Hikma Pharmaceuticals Plc (LON:HIK) insider Darwazah,Said purchased 70,251 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were purchased at an average cost of GBX 2,122 ($27.70) per share, for a total transaction of £1,490,726.22 ($1,945,863.75).
Darwazah,Said also recently made the following trade(s):
- On Friday, August 26th, Darwazah,Said bought 200,000 shares of Hikma Pharmaceuticals Plc stock. The stock was bought at an average cost of GBX 2,160 ($28.19) per share, for a total transaction of £4,320,000 ($5,638,950.53).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2152.00 on Tuesday. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00. The firm’s 50-day moving average price is GBX 2,252.71 and its 200-day moving average price is GBX 2,229.68. The stock’s market capitalization is GBX 4.86 billion.
A number of research analysts have recently issued reports on the company. Jefferies Group reissued a “buy” rating and issued a GBX 2,990 ($39.03) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 4th. Numis Securities Ltd reissued a “hold” rating and issued a GBX 2,660 ($34.72) target price on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, August 24th. Stifel Nicolaus reissued a “buy” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, June 24th. Barclays PLC reissued an “overweight” rating and issued a GBX 2,900 ($37.85) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 9th. Finally, Citigroup Inc. lowered Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) target price on the stock. in a report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of GBX 2,520.90 ($32.91).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.